Galvanize Therapeutics has raised $130m to advance its pulsed electric field (PEF) ablation technologies for oncology and chronic diseases.

The oversubscribed Series D financing round was led by growth equity firm HealthQuest Capital, with Braidwell LP and Olympus Innovation Ventures joining as new investors.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Additional contributions came from existing backers Ally Bridge Group, Elevage Medical Technologies, Fidelity Management & Research Company, Janus Henderson Investors, Longaeva Partners, Norwest, Perceptive Advisors, Sofinnova Partners, and T. Rowe Price Associates.

Proceeds from the investment will fund the commercial expansion of the Aliya platform in the US and the development of next-generation PEF systems.

The company also intends to allocate capital towards clinical evidence generation and the clinical progression of its RheOx therapy for chronic bronchitis.

The capital raise follows operational and regulatory milestones over the past year, including clearance from the US Food and Drug Administration (FDA) for the Aliya EX Generator and its subsequent commercial rollout.

Clinicians have completed more than 4,000 interventional procedures with the technology.

In addition, the business has recruited upwards of 300 participants into its PROPEL registry and contributed to more than 40 peer-reviewed papers evaluating PEF mechanisms of action, clinical outcomes, and potential therapeutic uses.

Designed for the surgical ablation of soft tissue, Aliya EX delivers brief, high-voltage electrical pulses designed to trigger non-thermal regulated cell death.

While preliminary clinical and laboratory findings indicate the technology may trigger antigen release capable of activating the immune system, whether this response delivers therapeutic benefit to patients remains unproven.

Galvanize Therapeutics chairman and CEO Doug Godshall said: “This financing marks an important inflection point for Galvanize. We’ve built a strong foundation with Aliya, demonstrating the potential of our PEF technology through growing physician adoption, commercial execution, and an expanding body of clinical evidence.

“This investment positions us to accelerate our growth and pursue our broader vision of expanding the impact of PEF across oncology and chronic disease. We’re grateful for the continued confidence of our investors as we enter this next phase of growth.”

In August 2024, Galvanize Therapeutics completed patient enrolment in the AFFINITY study assessing the Aliya PEF system in treating late-stage non-small cell lung cancer (NSCLC) and lung metastasis.